Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Anti-Cancer Drug market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Anti-Cancer Drug market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Anti-Cancer Drug market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Anti-Cancer Drug products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Anti-Cancer Drug products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Anti-Cancer Drug market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Anti-Cancer Drug development has been the leading industry trend of Anti-Cancer Drug market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Anti-Cancer Drug Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Avastin, Rituxan, Herceptin, Alimta |
| By Application Outlook |
Hospital, Clinic, Home Care, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Merck, Bristol-Myers Squibb, Bayer, GlaxoSmithKline, Novartis, Sanofi, Pfizer, Amgen, Celgene Corporation, Ariad Pharmaceuticals, Eli Lilly, Hoffmann-La Roche Ltd., AstraZeneca, Boehringer Ingelheim GmbH, Teva Pharmaceuticals |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Merck
- Bristol-Myers Squibb
- Bayer
- GlaxoSmithKline
- Novartis
- Sanofi
- Pfizer
- Amgen
- Celgene Corporation
- Ariad Pharmaceuticals
- Eli Lilly
- Hoffmann-La Roche Ltd.
- AstraZeneca
- Boehringer Ingelheim GmbH
- Teva Pharmaceuticals
Anti-Cancer Drug Market, By Type
- Avastin
- Rituxan
- Herceptin
- Alimta
Anti-Cancer Drug Market, By Application
- Hospital
- Clinic
- Home Care
- Other
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
1 Study Coverage
1.1 Anti-Cancer Drug Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Anti-Cancer Drug Market Size Growth Rate by Product
1.4.2 Avastin
1.4.3 Rituxan
1.4.4 Herceptin
1.4.5 Alimta
1.5 Market by End User
1.5.1 Global Anti-Cancer Drug Market Size Growth Rate by End User
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Home Care
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Anti-Cancer Drug Market Size
2.1.1 Global Anti-Cancer Drug Revenue 2017-2027
2.1.2 Global Anti-Cancer Drug Sales 2017-2027
2.2 Anti-Cancer Drug Growth Rate by Regions
2.2.1 Global Anti-Cancer Drug Sales by Regions
2.2.2 Global Anti-Cancer Drug Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Anti-Cancer Drug Sales by Manufacturers
3.1.1 Anti-Cancer Drug Sales by Manufacturers
3.1.2 Anti-Cancer Drug Sales Market Share by Manufacturers
3.1.3 Global Anti-Cancer Drug Market Concentration Ratio (CR5 and HHI)
3.2 Anti-Cancer Drug Revenue by Manufacturers
3.2.1 Anti-Cancer Drug Revenue by Manufacturers (2017-2020)
3.2.2 Anti-Cancer Drug Revenue Share by Manufacturers (2017-2020)
3.3 Anti-Cancer Drug Price by Manufacturers
3.4 Anti-Cancer Drug Manufacturing Base Distribution, Product Types
3.4.1 Anti-Cancer Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Anti-Cancer Drug Product Type
3.4.3 Date of International Manufacturers Enter into Anti-Cancer Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Anti-Cancer Drug Sales by Product
4.2 Global Anti-Cancer Drug Revenue by Product
4.3 Anti-Cancer Drug Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Anti-Cancer Drug Breakdown Data by End User
6 North America
6.1 North America Anti-Cancer Drug by Countries
6.1.1 North America Anti-Cancer Drug Sales by Countries
6.1.2 North America Anti-Cancer Drug Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Anti-Cancer Drug by Product
6.3 North America Anti-Cancer Drug by End User
7 Europe
7.1 Europe Anti-Cancer Drug by Countries
7.1.1 Europe Anti-Cancer Drug Sales by Countries
7.1.2 Europe Anti-Cancer Drug Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Anti-Cancer Drug by Product
7.3 Europe Anti-Cancer Drug by End User
8 Asia Pacific
8.1 Asia Pacific Anti-Cancer Drug by Countries
8.1.1 Asia Pacific Anti-Cancer Drug Sales by Countries
8.1.2 Asia Pacific Anti-Cancer Drug Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Anti-Cancer Drug by Product
8.3 Asia Pacific Anti-Cancer Drug by End User
9 Central & South America
9.1 Central & South America Anti-Cancer Drug by Countries
9.1.1 Central & South America Anti-Cancer Drug Sales by Countries
9.1.2 Central & South America Anti-Cancer Drug Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Anti-Cancer Drug by Product
9.3 Central & South America Anti-Cancer Drug by End User
10 Middle East and Africa
10.1 Middle East and Africa Anti-Cancer Drug by Countries
10.1.1 Middle East and Africa Anti-Cancer Drug Sales by Countries
10.1.2 Middle East and Africa Anti-Cancer Drug Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Anti-Cancer Drug by Product
10.3 Middle East and Africa Anti-Cancer Drug by End User
11 Company Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Company Business Overview
11.1.3 Merck Anti-Cancer Drug Sales, Revenue and Gross Margin (2017-2020)
11.1.4 Merck Anti-Cancer Drug Products Offered
11.1.5 Merck Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Company Business Overview
11.2.3 Bristol-Myers Squibb Anti-Cancer Drug Sales, Revenue and Gross Margin (2017-2020)
11.2.4 Bristol-Myers Squibb Anti-Cancer Drug Products Offered
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Company Business Overview
11.3.3 Bayer Anti-Cancer Drug Sales, Revenue and Gross Margin (2017-2020)
11.3.4 Bayer Anti-Cancer Drug Products Offered
11.3.5 Bayer Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 Company Business Overview
11.4.3 GlaxoSmithKline Anti-Cancer Drug Sales, Revenue and Gross Margin (2017-2020)
11.4.4 GlaxoSmithKline Anti-Cancer Drug Products Offered
11.4.5 GlaxoSmithKline Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Company Business Overview
11.5.3 Novartis Anti-Cancer Drug Sales, Revenue and Gross Margin (2017-2020)
11.5.4 Novartis Anti-Cancer Drug Products Offered
11.5.5 Novartis Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Details
11.6.2 Company Business Overview
11.6.3 Sanofi Anti-Cancer Drug Sales, Revenue and Gross Margin (2017-2020)
11.6.4 Sanofi Anti-Cancer Drug Products Offered
11.6.5 Sanofi Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Company Business Overview
11.7.3 Pfizer Anti-Cancer Drug Sales, Revenue and Gross Margin (2017-2020)
11.7.4 Pfizer Anti-Cancer Drug Products Offered
11.7.5 Pfizer Recent Development
11.8 Amgen
11.8.1 Amgen Company Details
11.8.2 Company Business Overview
11.8.3 Amgen Anti-Cancer Drug Sales, Revenue and Gross Margin (2017-2020)
11.8.4 Amgen Anti-Cancer Drug Products Offered
11.8.5 Amgen Recent Development
11.9 Celgene Corporation
11.9.1 Celgene Corporation Company Details
11.9.2 Company Business Overview
11.9.3 Celgene Corporation Anti-Cancer Drug Sales, Revenue and Gross Margin (2017-2020)
11.9.4 Celgene Corporation Anti-Cancer Drug Products Offered
11.9.5 Celgene Corporation Recent Development
11.10 Ariad Pharmaceuticals
11.10.1 Ariad Pharmaceuticals Company Details
11.10.2 Company Business Overview
11.10.3 Ariad Pharmaceuticals Anti-Cancer Drug Sales, Revenue and Gross Margin (2017-2020)
11.10.4 Ariad Pharmaceuticals Anti-Cancer Drug Products Offered
11.10.5 Ariad Pharmaceuticals Recent Development
11.11 Eli Lilly
11.12 Hoffmann-La Roche Ltd.
11.13 AstraZeneca
11.14 Boehringer Ingelheim GmbH
11.15 Teva Pharmaceuticals
12 Future Forecast
12.1 Anti-Cancer Drug Market Forecast by Regions
12.1.1 Global Anti-Cancer Drug Sales Forecast by Regions 2021-2027
12.1.2 Global Anti-Cancer Drug Revenue Forecast by Regions 2021-2027
12.2 Anti-Cancer Drug Market Forecast by Product
12.2.1 Global Anti-Cancer Drug Sales Forecast by Product 2021-2027
12.2.2 Global Anti-Cancer Drug Revenue Forecast by Product 2021-2027
12.3 Anti-Cancer Drug Market Forecast by End User
12.4 North America Anti-Cancer Drug Forecast
12.5 Europe Anti-Cancer Drug Forecast
12.6 Asia Pacific Anti-Cancer Drug Forecast
12.7 Central & South America Anti-Cancer Drug Forecast
12.8 Middle East and Africa Anti-Cancer Drug Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Anti-Cancer Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
